Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
68.88 EUR | -1.04% |
|
+14.49% | +51.03% |
03-13 | CARL ZEISS MEDITEC AG : Gets a Sell rating from JP Morgan | ZD |
03-12 | CARL ZEISS MEDITEC AG : Hauck & Aufhauser reiterates its Buy rating | ZD |
Capitalization | 6.09B 6.63B 5.83B 5.11B 9.5B 573B 10.47B 67.08B 25.53B 250B 24.88B 24.36B 994B | P/E ratio 2025 * |
37.5x | P/E ratio 2026 * | 29.4x |
---|---|---|---|---|---|
Enterprise value | 6.51B 7.09B 6.24B 5.46B 10.16B 612B 11.19B 71.71B 27.3B 267B 26.59B 26.04B 1,063B | EV / Sales 2025 * |
2.98x | EV / Sales 2026 * | 2.74x |
Free-Float |
40.86% | Yield 2025 * |
0.95% | Yield 2026 * | 1.17% |
Last Transcript: Carl Zeiss Meditec AG
1 day | -1.08% | ||
1 week | +14.49% | ||
Current month | +14.49% | ||
1 month | +25.11% | ||
3 months | +50.11% | ||
6 months | +21.79% | ||
Current year | +51.03% |







Manager | Title | Age | Since |
---|---|---|---|
Markus Weber
CEO | Chief Executive Officer | 52 | 30/12/2021 |
Director of Finance/CFO | 60 | 30/09/2018 | |
Chief Operating Officer | 46 | - |
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 09/04/2018 | |
Karl Lamprecht
CHM | Chairman | 61 | 26/05/2021 |
Isabel de Paoli
BRD | Director/Board Member | 51 | 24/06/2020 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-1.04% | +14.49% | -41.24% | -53.89% | 6.63B | ||
-0.59% | +1.12% | -11.04% | -12.00% | 196B | ||
+1.68% | -1.05% | +26.00% | +69.61% | 176B | ||
-1.18% | +2.59% | -17.14% | -28.04% | 150B | ||
+1.52% | +4.47% | +48.59% | +127.79% | 149B | ||
-2.44% | +0.55% | -6.29% | -8.10% | 64.33B | ||
-0.56% | +2.01% | -14.91% | -21.44% | 41.67B | ||
+0.80% | +3.49% | -24.82% | -37.13% | 41.68B | ||
+0.32% | -1.66% | -9.23% | - | 37.68B | ||
-0.72% | +1.97% | -17.08% | -12.15% | 34.84B | ||
Average | -0.26% | +2.83% | -6.72% | +2.74% | 89.76B | |
Weighted average by Cap. | -0.01% | +1.62% | +4.23% | +24.38% |
2025 * | 2026 * | |
---|---|---|
Net sales | 2.18B 2.38B 2.09B 1.83B 3.41B 205B 3.75B 24.06B 9.16B 89.62B 8.92B 8.74B 356B | 2.34B 2.55B 2.24B 1.97B 3.66B 220B 4.03B 25.81B 9.82B 96.16B 9.57B 9.37B 382B |
Net income | 153M 167M 147M 129M 239M 14.42B 264M 1.69B 643M 6.3B 627M 614M 25.05B | 204M 222M 195M 171M 318M 19.18B 351M 2.25B 856M 8.37B 834M 816M 33.31B |
Net Debt | 420M 458M 403M 353M 656M 39.51B 723M 4.63B 1.76B 17.25B 1.72B 1.68B 68.61B | 334M 364M 320M 281M 522M 31.42B 575M 3.68B 1.4B 13.72B 1.37B 1.34B 54.56B |
Date | Price | Change | Volume |
---|---|---|---|
20/03/25 | 68.75 € | -1.22% | 103,867 |
19/03/25 | 69.60 € | +2.35% | 189,524 |
18/03/25 | 68.00 € | +2.33% | 378,842 |
17/03/25 | 66.45 € | +3.67% | 235,235 |
14/03/25 | 64.10 € | +6.74% | 344,325 |
Delayed Quote Xetra, March 20, 2025 at 12:24 pm
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AFX Stock

MarketScreener is also available in this country: United States.
Switch edition